Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

44.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 44.37
Bid (Size) 40.50 (1)
Ask (Size) 48.00 (1)
Prev. Close 44.37
Today's Range 44.37 - 44.37
52wk Range 27.77 - 88.18
Shares Outstanding 70,468,961
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts 
From Beam Therapeutics
Via Globe NewsWire
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga

Performance

YTD
-46.00%
-46.00%
1 Month
+17.04%
+17.04%
3 Month
-16.17%
-16.17%
6 Month
+23.63%
+23.63%
1 Year
-35.63%
-35.63%

More News

Read More
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
From Beam Therapeutics
Via Globe NewsWire
Beam Therapeutics's Return On Capital Employed Insights
Via Benzinga
Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy
Via Benzinga
Why Beam Therapeutics Stock Is Falling Today
Via The Motley Fool
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Beam Therapeutics
Via Globe NewsWire
A Sitcom Character Inspired This Investor
Via The Motley Fool
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via Globe NewsWire
Beam Therapeutics: Q3 Earnings Insights
Via Benzinga
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
Via Benzinga
Beam Therapeutics to Participate in Upcoming Investor Conferences
From Beam Therapeutics
Via Globe NewsWire
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why Beam Therapeutics Stock Is Falling Today
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
From Beam Therapeutics
Via Globe NewsWire
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
From Beam Therapeutics
Via Globe NewsWire
ON Semiconductor, Global Payments And Other Big Losers From Monday
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Via Investor's Business Daily
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apple, Amazon, HP And Other Big Losers From Friday
Via Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Via Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.